Chemotherapie-Visualisierer v5.0 Chemotherapy Visualizer v5.0
Select active ingredients → active ingredient-specific laboratory parameters appear automatically.
[S] = schematic/interpolated · All cycles : Multi-cycle continuum view with cumulative Hb decrease & anthracycline limit monitor · Left in hover text
Select agent → agent-specific lab parameters appear automatically.
[S] = schematic/interpolated · All cycles : Multi-cycle continuum view with cumulative Hb decline & anthracycline limit monitor · References in hover text
Vergleich A|B
Schema A und B wählen - Toxizitätsvergleich erscheint hier. Select schema A and B - toxicity comparison appears here.
Selected active ingredients
No active ingredients selected yet
Selected active ingredients Selected agents
Schema wählen - Wirkstoffe erscheinen hier
► Patient Profile & Organ Function Patient profile & organ function Baseline & Dose Adjustment Baseline & dose adjustment Individual starting values before the start of therapy Individual baseline values before therapy start Reset
Patientenkennung & Datenspeicherung
Speichern / Save
Laden / Load
Löschen / Delete
Hematology
Datum & Zyklusposition
Performance Status & Gewichtsverlauf
Vorherige Anthrazyklin-Exposition
Kidney function
Liver function
More output values
Medication adherence
Z1 Z2 Z3 Z4 Z5 Z6
Reason Reason Kidney Cardio Infection
U
Calvert (Carboplatin) Calvert (Carboplatin) Dosis (mg) = AUC × (GFR + 25)
AUC:
5 (1.L) 6 (adj.) 4 (2.L) 2 (wkly)
GO
GFR aus GFR-Rechner verwenden
FN-Risiko (EORTC/ASCO) Wirkstoff wählen → Select agent →
Empfohlene Labortage Recommended lab days Wirkstoff wählen → empfohlene Blutbild-Abnahmetage erscheinen hier Select agent → recommended lab days appear here
Kumulative Nephrotoxizität (Cisplatin) Cumulative nephrotoxicity (Cisplatin)
Genetic polymorphisms
- Gen wählen - - Select gene - TPMT (6-Mercaptopurine) DPYD (5-FU / Capecitabine) UGT1A1 (Irinotecan) NUDT15 (Thiopurine, bes. asiatische Pat.) CYP3A4 (Doxo, Etoposide, Vincristine, etc.)
Normal / Wild-type Heterozygous Deficient / Poor metabolizer
+ Add + Add
DPYD Stufendiagnostik (FDA 2022)
Dosisanpassung Leberinsuffizienz Dose adjustment hepatic impairment
Kumulative Cisplatin-Ototoxizität Cumulative cisplatin ototoxicity
Antiemese-Empfehlung (MASCC/ASCO/NCCN)
Wirkstoff wählen - Antiemese-Regime erscheint automatisch. Select agent - antiemetic regimen appears automatically.
Tumorlyse-Syndrom Risiko (Cairo-Bishop)
Wirkstoff wählen - TLS-Risikoeinschätzung erscheint automatisch. Select agent - TLS risk assessment appears automatically.
Interactions Drug interactions
Is automatically checked once multiple active ingredients have been selected. Checked automatically when multiple agents are selected.
AI Prognosis Model (Nomographic)
Compute Prognosis
Recommendations
↑ Select active ingredient to start visualization ↑ Select agent to start visualization